ISRG
INTUITIVE SURGICAL INC
Nasdaq: ISRG · Sunnyvale, CA
$426.61+8.00 (+1.91%)Closed
Market Cap$151.16B
Cash$4.52Bmost recent
Runwayprofitable
P/E (TTM)54.2EPS $7.87
52-Wk Range$402.30 – $592.85
Avg Volume2.1M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$426.61+2.0%
Pipeline

Drug candidates sponsored by INTUITIVE SURGICAL · ClinicalTrials.gov

55 drugs · 58 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3IS-001
Ureter Injury+2 more
Completed
2025-01-31past
4
Phase 3filricianine
Ureter Injury
Not yet recruiting
2027-04-30
1
Phase 1Unnamed
Prostate and Kidney Cancer
Completed
2013-10past
1
Phase 2Administration of IS-002
Prostate Cancer
Completed
2024-05-21past
1
Phase 1IS-002
Prostate Cancer
Completed
2021-09-20past
1
N/AUnnamed
Renal Tumors
Withdrawn
2010-07past
1
N/AIndocyanine green (ICG)
Gallbladder Disease+2 more
Completed
2012-12past
1
N/AUnnamed
Subjects Who Have Undergone Benign Non-tumor TORS Procedures Using the da Vinci Surgical System
Completed
2014-02past
1
N/AUnnamed
Hernia, Inguinal+2 more
Completed
2016-06past
1
N/AUnnamed
Sigmoid Diseases
Completed
2016-07past
1
N/AUnnamed
Symptomatic Gallbladder Disease
Completed
2016-12past
1
N/AUnnamed
Colonic Neoplasms+1 more
Completed
2017-09past
1
N/AUnnamed
Oropharyngeal Cancer
Completed
2017-11-14past
1
N/AUnnamed
Lung Cancer
Completed
2020-07-01past
1
N/AUnnamed
Benign Colon Tumor+2 more
Completed
2021-07-21past
1
N/AUnnamed
Cholecystectomy
Completed
2021-09-30past
1
N/AUnnamed
Renal Cancer
Terminated
2021-12-15past
1
N/AUnnamed
Benign Right Colon Disease+1 more
Completed
2022-02-14past
1
N/AUnnamed
Bariatric Surgery Candidate
Completed
2022-03-01past
1
N/AUnnamed
Bariatric Surgery Candidate
Completed
2022-03-15past
1
N/AUnnamed
Pulmonary Nodule+2 more
Unknown
2022-05-26past
1
N/AUnnamed
Lung Cancer+1 more
Completed
2022-06-30past
1
N/AUnnamed
Bariatric Surgery Candidate
Completed
2022-09-22past
1
N/AUnnamed
Hernia+4 more
Completed
2022-10past
1
N/AUnnamed
Prostate Cancer
Completed
2022-11-10past
1
N/AUnnamed
Lung Cancer+1 more
Completed
2022-12-31past
1
N/AUnnamed
Obstructive Sleep Apnea
Completed
2023-01-25past
1
N/AUnnamed
Kidney Cancer
Completed
2023-02-03past
1
N/AUnnamed
Lung Cancer
Completed
2023-04-30past
1
N/AUnnamed
Thymoma+9 more
Active, not recruiting
2023-05-24past
1
N/AUnnamed
Primary Lung Cancer+3 more
Active, not recruiting
2023-06-16past
1
N/AUnnamed
Inguinal Hernia
Completed
2023-07-06past
1
N/AUnnamed
Prophylactic Nipple Sparing Mastectomy (NSM)
Terminated
2023-07-18past
1
N/AUnnamed
Colorectal Cancer+1 more
Active, not recruiting
2023-09-30past
1
N/AUnnamed
Ventral Hernia
Completed
2023-11-09past
1
N/AUnnamed
Lung Cancer
Completed
2023-12-31past
1
N/AUnnamed
Lung Cancer
Completed
2024-04-11past
1
N/AUnnamed
Left-sided Colorectal Resection : Diverticular Diseases+2 more
Completed
2024-05-21past
1
N/AUnnamed
Hernia, Inguinal
Unknown
2024-05-31past
1
N/AUnnamed
Ventral Hernia
Terminated
2024-11-04past
1
N/AUnnamed
Lung Cancer
Active, not recruiting
2025-01-24past
1
N/AUnnamed
Laparoscopic Cholecystectomy+1 more
Completed
2025-01-27past
1
N/AUnnamed
Thoracic+1 more
Completed
2025-11-09past
1
N/AUnnamed
Pulmonary Nodule, Solitary+1 more
Active, not recruiting
2025-12-10past
1
N/AUnnamed
Breast Cancer Female+4 more
Active, not recruiting
2026-03past
1
N/AUnnamed
Imaging
Completed
2026-03-27past
1
N/AUnnamed
Acute Appendicitis
Recruiting
2026-07-31
1
N/AUnnamed
Hernia, Inguinal+5 more
Recruiting
2026-08
1
N/AUnnamed
GYN Disorders
Withdrawn
2026-11
1
N/AUnnamed
Nipple Sparing Mastectomy
Active, not recruiting
2026-12-31
1
N/AUnnamed
Nipple Sparing Mastectomy
Active, not recruiting
2027-04-30
1
N/AUnnamed
Lung Cancer+8 more
Active, not recruiting
2027-08
1
N/AUnnamed
GYN Disorders
Recruiting
2027-12
1
N/AUnnamed
Lung Cancer
Recruiting
2027-12-30
1
N/AUnnamed
Pulmonary Nodule+1 more
Recruiting
2029-10
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for ISRG. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.